ML-7 hydrochloride: Selective MLCK Inhibitor for Cardiovascular and Cellular Motility Research

Executive Summary: ML-7 hydrochloride (A3626) is a highly selective inhibitor of myosin light chain kinase (MLCK), with a Ki of 300 nM, enabling precise modulation of MLCK activity in vitro and in vivo [APExBIO]. It blocks MLCK-mediated phosphorylation of myosin light chain (MLC), a critical step in muscle contraction and cellular motility [Liu et al., 2021]. ML-7 hydrochloride improves cardiac contractility and mitigates ischemia/reperfusion injury in preclinical models [internal]. The compound is soluble in DMSO and water but not ethanol, with optimal storage at -20°C to maintain stability [APExBIO]. ML-7 hydrochloride is intended for research use only and is supplied with ≥98% purity.

Biological Rationale

MLCK catalyzes the phosphorylation of myosin regulatory light chains, a process essential for actin-myosin cross-bridge cycling in smooth muscle and non-muscle cells. Dysregulation of MLCK activity contributes to pathophysiological states such as cardiovascular disease, ischemia/reperfusion (I/R) injury, vascular endothelial dysfunction, and cancer cell invasion [Liu et al., 2021]. In disease models, selective MLCK inhibition allows researchers to probe the specific contribution of the MLCK/MLC axis without impinging on unrelated kinases. ML-7 hydrochloride, developed and supplied by APExBIO, addresses this need by offering high selectivity and reproducibility [APExBIO].

Mechanism of Action of ML-7 hydrochloride

ML-7 hydrochloride (1-((5-iodonaphthalen-1-yl)sulfonyl)-1,4-diazepane hydrochloride) competitively binds to the ATP-binding site of MLCK, inhibiting its kinase activity with a Ki of 300 nM [APExBIO]. This inhibition prevents the phosphorylation of myosin light chain (MLC), disrupting the actin-myosin interaction required for cellular contraction and motility. Downstream effects include reduced contractility in cardiac and smooth muscle cells and suppression of cell migration and invasion in cancer models [Liu et al., 2021]. ML-7's selectivity profile has been validated against related kinases such as ROCK and PKC, with minimal off-target inhibition at working concentrations [internal].

Evidence & Benchmarks

• ML-7 hydrochloride inhibits MLCK activity with a Ki of 300 nM, as determined by in vitro kinase assays (APExBIO, product page).
• In breast cancer cells, ML-7 reverses QPRT-induced myosin light chain phosphorylation and cell invasion at 10 μM, confirming pathway specificity (Liu et al., 2021, DOI).
• Pre-treatment with ML-7 improves contractile function and attenuates oxidative stress in rat models of cardiac I/R injury (see discussion, internal).
• ML-7 ameliorates endothelial dysfunction and atherosclerosis in rabbit models by regulating ZO1 and occludin tight junction proteins (internal).
• ML-7 is soluble in DMSO (≥15.95 mg/mL) and water (≥8.82 mg/mL with gentle warming and ultrasonic treatment), but insoluble in ethanol (APExBIO).

This article extends the mechanistic focus of "ML-7 Hydrochloride: Redefining MLCK Inhibition for Breakthroughs" by providing updated solubility, storage, and benchmarking data. It clarifies the selectivity findings discussed in "ML-7 Hydrochloride: Selective MLCK Inhibitor for Cardiovascular Research" by adding peer-reviewed data on cancer cell models. New in vivo endpoints highlighted here complement the translational perspective of "ML-7 Hydrochloride: Enabling Mechanistic Breakthroughs and Discovery".

Applications, Limits & Misconceptions

ML-7 hydrochloride is routinely used to dissect the MLCK/MLC pathway in cardiovascular, vascular, and cancer models. Applications include:

• Studying ischemia/reperfusion injury in rodent cardiac models.
• Modeling vascular endothelial dysfunction and atherosclerosis in rabbits.
• Assessing cell motility and invasion in cancer cell lines.
• Regulating tight junction protein expression (ZO1, occludin) via MLCK inhibition.

Common Pitfalls or Misconceptions

• ML-7 is not effective for inhibiting other kinases such as ROCK or PKC at standard concentrations; separate controls are required.
• Insoluble in ethanol; attempting to dissolve ML-7 hydrochloride in ethanol leads to precipitation and reduced activity.
• Activity may decline in aqueous solutions stored for more than 48 hours at room temperature; always prepare fresh or store at -20°C for maximal efficacy.
• Not for diagnostic or clinical use; research use only as specified by APExBIO.
• Over-interpretation of results can occur if off-target effects at supra-physiological concentrations (>50 μM) are not controlled.

Workflow Integration & Parameters

For optimal results, dissolve ML-7 hydrochloride in DMSO to at least 15.95 mg/mL or in water (≥8.82 mg/mL) using gentle warming and sonication. Use working concentrations between 1 μM and 50 μM, depending on cell type and endpoint. Store powder at -20°C and use solutions freshly or within 24–48 hours. ML-7’s high purity (≥98%) ensures reproducibility across replicates [APExBIO]. Adhere to local regulations and safety protocols for handling kinase inhibitors.

Conclusion & Outlook

ML-7 hydrochloride remains the reference selective MLCK inhibitor for cardiovascular and cell motility research. Its well-characterized mechanism, robust solubility, and high purity make it indispensable for dissecting MLCK-mediated signaling. As new disease models emerge, ML-7 will continue to facilitate mechanistic breakthroughs and translational discovery. For more details or to order, visit the ML-7 hydrochloride product page on APExBIO.